Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfabromomethazine is a synthetic sulfonamide antibacterial agent primarily used in veterinary medicine. It is structurally related to other sulfonamides such as sulfamethazine and acts as a competitive inhibitor of the enzyme dihydropteroate synthase. By mimicking para-aminobenzoic acid (PABA), it blocks the synthesis of dihydrofolic acid, an essential precursor for bacterial folate production and DNA synthesis. This results in bacteriostatic activity against susceptible organisms. Sulfabromomethazine has been used to treat and prevent various bacterial infections in food-producing animals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfabromomethazine.